A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2-Reference-Cited by-同舟云学术

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2

Published:2022-11-11 Issue:1 Volume:11 Page:2724-2734
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Wang Shixia¹,Wang Chang Yi²³,Kuo Hui-Kai²,Peng Wen-Jiun²,Huang Juin-Hua²,Kuo Be-Shen³,Lin Feng⁴,Liu Yaw-Jen³,Liu Zhi⁴,Wu Huang-Ting²,Ding Shuang⁴,Hou Kou-Liang²,Cheng Jennifer²,Yang Ya-Ting²,Jiang Ming-Han²,Wang Min-Sheng²,Chen Tony²,Xia Wei Guo⁴,Lin Ed⁴,Hung Chung Ho⁴,Chen Hui-Jung³,Shih Zhonghao³,Lin Yi Ling⁵,Ryan Valorie¹,Hu Mei Mei¹⁴,Heppner D. Gray¹,Malherbe Delphine C.⁶⁷,Periasamy Sivakumar⁶⁷,Kuzmina Natalia⁶⁷,Subramani Chandru⁶⁷,Hellerstein Michael¹,Monath Thomas P.¹,Rumyantsev Alexander¹,Bukreyev Alexander⁶⁸⁷,Guirakhoo Farshad¹

Affiliation:

1. Vaxxinity, Inc., Dallas, TX, USA

2. United Biomedical Inc., Asia, Taipei, Taiwan

3. United BioPharma, HuKo, Taiwan

4. United Biomedical Inc., Hauppauge, NY, USA

5. Emerging Infectious Disease Division, Academia Sinica, Nangang, Taiwan

6. Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA

7. Galveston National Laboratory, Galveston, TX, USA

8. Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2022.2140608

Reference39 articles.

1. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

2. How well can Omicron evade immunity from COVID vaccines?

3. Antibody evasion properties of SARS-CoV-2 Omicron sublineages

4. Control ECfDPa. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. https://wwwecdceuropaeu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5. 2022.

5. https://covid19.trackvaccines.org/. 2022.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation Dengue Vaccines: Leveraging Peptide-Based Immunogens and Advanced Nanoparticles as Delivery Platforms;Journal of Pharmaceutical Sciences;2024-08

2. CHO cells for virus-like particle and subunit vaccine manufacturing;Vaccine;2024-04

3. Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines;Autoimmunity Reviews;2024-03

4. UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease;iScience;2024-02

5. COVID-19 Vaccines: Where Did We Stand at the End of 2023?;Viruses;2024-01-29